512 related articles for article (PubMed ID: 22228332)
1. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
2. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
3. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
5. Influence of thyroid-stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer cells in vitro.
Kim CH; Yoo IeR; Chung YA; Park YH; Kim SH; Sohn HS; Chung SK
Ann Nucl Med; 2009 Feb; 23(2):131-6. PubMed ID: 19225935
[TBL] [Abstract][Full Text] [Related]
6. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between FDG PET /CT and the expression of glutl and ki-67 antigen in esophageal cancer].
Mu DB; Wang SP; Yang WF; Fu Z; Chen XX; Sun XR; Yu JM
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):30-3. PubMed ID: 17575690
[TBL] [Abstract][Full Text] [Related]
10. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.
Moon SH; Oh YL; Choi JY; Baek CH; Son YI; Jeong HS; Choe YS; Lee KH; Kim BT
Endocr Res; 2013; 38(2):77-84. PubMed ID: 22888973
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer].
Duan Y; Yu LJ; Lu PO; Wang WZ
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):764-7. PubMed ID: 19173807
[TBL] [Abstract][Full Text] [Related]
14. Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer.
Kim BH; Kim IJ; Kim SS; Kim SJ; Lee CH; Kim YK
Cancer Biother Radiopharm; 2010 Jun; 25(3):309-15. PubMed ID: 20578836
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
16. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma.
Lansoy-Kuhn C; Picquenot JM; Edet-Sanson A; Mechken F; Laberge-Le Couteulx S; Cornic M; Vera P
Nucl Med Commun; 2013 Apr; 34(4):340-6. PubMed ID: 23407367
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
19. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
Deandreis D; Al Ghuzlan A; Leboulleux S; Lacroix L; Garsi JP; Talbot M; Lumbroso J; Baudin E; Caillou B; Bidart JM; Schlumberger M
Endocr Relat Cancer; 2011 Feb; 18(1):159-69. PubMed ID: 21118976
[TBL] [Abstract][Full Text] [Related]
20. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
